Revance to Release Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
Rhea-AI Summary
RVNC: Revance Therapeutics to Release Q2 2023 Financial Results on August 8, 2023; Conference Call Scheduled for Same Day at 4:30 p.m. ET. Webcast Replay Available Until November 9, 2023
08/01/2023 - 08:00 AM
Conference Call Scheduled for Tuesday, August 8, 2023 at 4:30 p.m. ET.
NASHVILLE, Tenn. --(BUSINESS WIRE)--
Revance Therapeutics, Inc. (RVNC), today announced that the company will release second quarter 2023 financial results on Tuesday, August 8, 2023, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update.
Individuals interested in listening to the conference call may do so by dialing (888) 330-3637 for U.S. and Canadian callers, and reference conference ID 5680588 or from the webcast link in the investor relations section of the company's website at: www.revance.com .
A webcast replay will be available beginning August 8, 2023, at 4.30 p.m. PT / 7.30 p.m. ET to November 9, 2023 at 4.30 p.m. PT / 7.30 p.m. ET. To access the replay, please register via the webcast link on the events page. The webcast will be available in the investor relations section on the company's website for 90 days following the completion of the call.
About Revance
Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that elevate patient and physician experiences. Revance’s aesthetics portfolio of expertly created products and services, including DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection, the RHA® Collection of dermal fillers, and OPUL®, the first-of-its-kind Relational Commerce platform for aesthetic practices, deliver a differentiated and exclusive offering for the company’s elite practice partners and their consumers. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection, which will compete in the existing short-acting neuromodulator marketplace. Revance’s therapeutics pipeline is currently focused on muscle movement disorders including evaluating DAXXIFY® in two debilitating conditions, cervical dystonia and upper limb spasticity.
Revance is headquartered in Nashville, Tennessee , with additional office locations in Newark and Irvine, California . Learn more at www.Revance.com , www.RevanceAesthetics.com , www.DAXXIFY.com , or connect with us on LinkedIn .
“Revance” and the Revance logo, DAXXIFY®, and OPUL® are registered trademarks of Revance Therapeutics, Inc.
Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230801816173/en/
Investors
jessica.serra@revance.com
laurence@gilmartinir.com
Media
sfahy@revance.com
Source: Revance Therapeutics, Inc.
What is the date of the conference call for Revance Therapeutics, Inc. (RVNC)?
The conference call is scheduled for Tuesday, August 8, 2023 at 4:30 p.m. ET.
How can individuals listen to the conference call for Revance Therapeutics, Inc. (RVNC)?
Interested individuals may listen to the conference call by dialing (888) 330-3637 for U.S. and Canadian callers, and reference conference ID 5680588 or from the webcast link in the investor relations section of the company's website at: www.revance.com.
Until when is the webcast replay available for Revance Therapeutics, Inc. (RVNC)?
The webcast replay will be available beginning August 8, 2023, at 4.30 p.m. PT / 7.30 p.m. ET to November 9, 2023 at 4.30 p.m. PT / 7.30 p.m. ET.
RVNC Rankings
#5006 Ranked by Stock Gains
RVNC Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Other, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
United States
City
Nashville
About RVNC
revance therapeutics, inc. is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. the company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented transmts® peptide delivery system to address unmet needs in the $3 billion neurotoxin market. revance's proprietary transmts technology enables delivery of botulinum toxin a through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. revance is currently pursuing clinical development for two product candidates, topical rt001 and injectable rt002, in a broad spectrum of aesthetic and therapeutic indications. rt001 is a topical gel, which has the potential to be the first commercially available non-injectable dose form
